Protective effects of butanol fraction from Betula Platyphyla var. japonica on cartilage alterations in a rabbit collagenase-induced osteoarthritis

Journal of Ethnopharmacology

Volumn 123, Issue 3, 2009, Pages 515-521

  Huh, Jeong Eun ^a   Baek, Yong Hyeon ^b   Kim, Yeo Jin ^a   Lee, Jae Dong ^a   Choi, Do Young ^a   Park, Dong Suk ^b  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

Author keywords

Butanol fraction from the bark of Betula platyphylla var. japonica; Cartilage alternations; Cyclooxygenase; MMPs; PGE2; TIMP 1

Indexed keywords

BETULA PLATYPHYLA EXTRACT; BUTANOL; CELECOXIB; COLLAGENASE; CYCLOOXYGENASE 2; INTERSTITIAL COLLAGENASE; MESSENGER RNA; PLANT EXTRACT; PROSTAGLANDIN E2; PROTEOGLYCAN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BARK; CARTILAGE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; KNEE OSTEOARTHRITIS; MALE; NONHUMAN; PROTEIN EXPRESSION; RABBIT; RAT; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RIGIDITY; SYNOVIAL FLUID;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BETULA; CARTILAGE, ARTICULAR; COLLAGENASES; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; OSTEOARTHRITIS; PHYTOTHERAPY; PLANT BARK; PLANT EXTRACTS; PLANTS, MEDICINAL; PROTEOGLYCANS; PYRAZOLES; RABBITS; RNA, MESSENGER; SULFONAMIDES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

BETULA; BETULA PLATYPHYLLA VAR. JAPONICA; JAPONICA; ORYCTOLAGUS CUNICULUS;

EID: 67349157681     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2008.08.028     Document Type: Article

References (42)

1. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., and Schnitzer T.J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New England Journal of Medicine 343 (2000) 1520-1528
2. Cho Y.J., Huh J.E., Kim D.Y., Kim N.J., Lee J.D., Baek Y.H., Cho E.M., Yang H.R., Choi D.Y., and Park D.S. Effect of Betula platyphylla var. japonica on proteoglycan release, type II collagen degradation, and matrix metalloproteinase expression in rabbit articular cartilage explants. Biological and Pharmaceutical Bulletin 29 (2006) 1408-1413
3. Colombo C., Butler M., O'Byrne E., Hickman L., Swartzendruber D., Selwyn M., and Steinetz B. A new model of osteoarthritis in rabbits. I. Development of knee joint pathology following lateral meniscectomy and section of the fibular collateral and sesamoid ligaments. Arthritis Rheumatism 26 (1983) 875-886
4. Dean D.D., Martel-Pelletier J., Pelletier J.P., Howell D.S., and Woessner J.F. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. Journal of Clinical Investigation 84 (1989) 678-685
5. Dumond H., Presle N., Pottie P., Pacquelet S., Terlain B., Netter P., Gepstein A., Livne E., and Jouzeau J.Y. Site specific change in gene expression and cartilage metabolism during early experimental osteoarthritis. Osteoarthritis Cartilage 12 (2004) 284-295
6. El Hajjaji H., Marcelis A., Devogelaer J.P., and Manicourt D.H. Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. Journal of Rheumatology 30 (2003) 2444-2451
7. Faour W.H., He Q., Mancini A., Jovanovic D., Antoniou J., and Di Battista J.A. Prostaglandin E2 stimulates p53 transactivational activity through specific serine 15 phosphorylation in human synovial fibroblasts. Role in suppression of c/EBP/NF-kappaB-mediated MEKK1-induced MMP-1 expression. Journal of Biological Chemistry 281 (2006) 19849-19860
8. Farkouh M.E., Kirshner H., Harrington R.A., Ruland S., Verheugt F.W., Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., Ehrsam E., Gitton X., Krammer G., Mellein B., Gimona A., Matchaba P., Hawkey C.J., and Chesebro J.H. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364 (2004) 675-684
9. Fung H.B., and Kirschenbaum H.L. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. Clinical Therapeutics 21 (1999) 1131-1157
10. Hardy M.M., Seibert K., Manning P.T., Currie M.G., Woerner B.M., Edwards D., Koki A., and Tripp C.S. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheumatism 46 (2002) 1789-1803
11. Hashimoto G., Aoki T., Nakamura H., Tanzawa K., and Okada Y. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Letter 494 (2001) 192-195
12. Huh J. Dong Ui Bo Gam [The Precious Mirror of Oriental Medicine] (1999 (1613 A.D.)), Namsangdang, Seoul
13. Hungin A.P., and Kean W.F. Nonsteroidal anti-inflammatory drugs: overused or underused in osteoarthritis?. The American Journal of Medicine 110 (2001) 8S-11S
14. Ishikawa T., Nishigaki F., Miyata S., Hirayona Y., Minoura K., Imanishi J., Neya M., Mizutani T., Imamura Y., Ohkubo Y., and Mutoh S. Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR 255031. European Journal of Pharmacology 144 (2005) 133-143
15. Isiguro N., Ito T., Iwata H., Jugessur H., Ionescu M., and Poole A.R. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis. Arthritis Rheumatism 42 (1999) 129-136
16. Iyer S., Wei S., Brew K., and Acharya K.R. Crystal structure of the catalytic domain of matrix metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloproteinase-1. Journal of Biological Chemistry 282 (2007) 364-371
17. Ju E.M., Lee S.E., Hwang H.J., and Kim J.H. Antioxidant and anticancer activity of extract from Betula platyphylla var. japonica. Life Science 74 (2004) 1013-1026
18. Kikuchi T., Yamada H., and Shimmei M. Effect of high molecular weight hyaluronan on cartilage degeneration in a rabbit model of osteoarthritis. Osteoarthritis Cartilage 6 (1998) 177-186
19. Kim H.C. Herbalogy (2000), Young Lim Sa, Seoul
20. Kim J.H., Ryu K.H., Jung K.W., Han C.K., Kwak W.J., and Cho Y.B. SKI306X suppresses cartilage destruction and inhibits the production of matrix metalloproteinase in rabbit joint cartilage explant culture. Journal of Pharmacological Sciences 98 (2005) 298-306
21. Lark M.W., Bayne E.K., Flanagan J., Harper C.F., Hoerrner L.A., Hutchinson N.I., Singer I.I., Donatelli S.A., Weidner J.R., Williams H.R., Mumford R.A., and Lohmander L.S. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. Journal of Clinical Investigation 100 (1997) 93-106
22. Lazzaroni M., and Bianchi Porro G. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Alimentent Pharmacological Therapy 20 (2004) 48-58
23. Lu H.T., Liang Y.C., Sheu M.T., Ho H.O., Lin Y.T., Hsieh M.S., and Chen C.H. Disease-modifying effects of glucosamine HCl involving regulation of metalloproteinases and chemokines activated by interleukin-1beta in human primary synovial fibroblasts. Journal of Cellular Biochemistry 104 (2008) 38-50
24. Marcus D.M., and Grollman A.P. Botanical medicines-the need for new regulations. New England Journal of Medicine 347 (2002) 2073-2076
25. Mastbergen S.C., Lafeber F.P., and Bijlsma J.W. Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage. Rheumatology (Oxford) 41 (2002) 801-808
26. Mastbergen S.C., Bijlsma J.W., and Lafeber F.P. Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study. Osteoarthritis Cartilage 13 (2005) 519-526
27. Mastbergen S.C., Jansen N.W., Bijlsma J.W., and Lafeber F.P. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Research and Therapy 8 (2006) R2
28. Mastbergen S.C., Marijnissen A.C., Vianen M.E., Zoer B., van Roermund P.M., Bijlsma J.W., and Lafeber F.P. Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis. Rheumatology (Oxford) 45 (2006) 405-413
29. Panico A.M., Vicini P., Massimo G., Cardile V., Gentile B., Avondo S., Vittorio F., and Ronsisvalle G. Protective effects of benzisothiazolylamidines on IL-1 beta induced alterations in human articular chondrocyte metabolism. Inflammation 28 (2004) 231-235
30. Pastoureau P., Leduc S., Chomel A., and De Ceuninck F. Quantitative assessment of articular cartilage and subchondral bone histology in the meniscectomized guinea pig model of osteoarthritis. Osteoarthritis Cartilage 11 (2003) 412-423
31. Poole A.R. Cartilage in health and disease. In: Koopman W.J. (Ed). Arthritis and Allied Conditions: A Textbook of Rheumatology. 14th ed. (2000), Lippincott Williams & Wilkins, Philadelphia 226-284
32. Poole A.R. An introduction to the pathophysiology of osteoarthritis. Frontiers in Bioscience 4 (1999) D662-670
33. Quandt S.A., Chen H., Grzywacz J.G., Bell R.A., Lang W., and Arcury T.A. Use of complementary and alternative medicine by persons with arthritis: results of the National Health Interview Survey. Arthritis Rheumatism 53 (2005) 748-755
34. Roberts S., Caterson B., Menage J., Evans E.H., Jaffray D.C., and Eisenstein S.M. Matrix metalloproteinases and aggrecanase: their role in disorders of the human intervertebral disc. Spine 25 (2000) 3005-3013
35. Sabatini M., Lesur C., Thomas M., Chomel A., Anract P., de Nanteuil G., and Pastoureau P.P. Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in a guinea pig model of osteoarthritis. Arthritis Rheumatism 52 (2005) 171-180
36. Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., Ehrsam E., Gitton X., Krammer G., Mellein B., Matchaba P., Gimona A., Hawkey C.J., and TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
37. Swanson C.A. Suggested guidelines for articles about botanical dietary supplements. American Journal of Clinical Nutrition 75 (2002) 8-10
38. Tapsell L.C., Hemphill I., Cobiac L., Patch C.S., Sullivan D.R., Fenech M., Roodenrys S., Keogh J.B., Clifton P.M., Williams P.G., Fazio V.A., and Inge K.E. Health benefits of herbs and spices: the past, the present, the future. The Medicinal Journal of Australia 185 (2006) S4-24
39. Westacott C.I., and Sharif M. Cytokines in osteoarthritis: mediators on markers of joint destruction. Seminar Arthritis Rheumatism 25 (1996) 254-272
40. Woessner J.F. Matrix metalloproteinase and their inhibitors in connective tissue remodeling. FASEB Journal 5 (1991) 2145-2154
41. Wu H., Du J., and Zheng Q. Expression of MMP-1 in cartilage and synovium of experimentally induced rabbit ACLT traumatic osteoarthritis: immunohistochemical study. Rheumatology International Clinical and Experimental Investigations (2008) (July, Epub. ahead of print)
42. Xu H.T., Chen Y., Chen L.K., Li J.Y., Zhang W., and Wu B. Effect of various intervention factors on MMP-3 and TIMP-1 level in synovial fluid in knee joints with osteroarthritis. Zhong Nan Da Xue Xue Bao Yi Xue Ban 33 (2008) 47-52